Ignyta is a precision medicine company focused on oncology. It aims to test, identify and treat patients with cancers harboring specific rare mutations. Ignyta’s lead molecule entrectinib is an orally bioavailable, CNS-active tyrosine kinase inhibitor targeting tumors that harbor ROS1 or NTRK fusions.
Per the agreement, Roche will commence a tender offer to acquire all of the outstanding shares of Ignyta’s common stock. After completion of the tender offer, Roche will acquire all remaining shares through a second step merger.
The deal is expected to close in the first half of 2018.
More articles on data analytics & precision medicine:
FTC issues privacy warning over direct-to-consumer genetic tests
Former IBM Watson oncologist named VP of precision medicine startup: 4 things to know
UNC researchers find Watson for Genomics tech useful for identifying potential therapies
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
